Patents by Inventor Richard I. Senderoff
Richard I. Senderoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220133891Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: January 12, 2022Publication date: May 5, 2022Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 11246938Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: GrantFiled: March 4, 2019Date of Patent: February 15, 2022Assignee: Baxter International Inc.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Publication number: 20190192667Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: March 4, 2019Publication date: June 27, 2019Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 10232046Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: GrantFiled: March 20, 2017Date of Patent: March 19, 2019Assignee: Baxter International Inc.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 10124068Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: GrantFiled: March 20, 2017Date of Patent: November 13, 2018Assignee: Baxter International, Inc.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Publication number: 20170189537Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: March 20, 2017Publication date: July 6, 2017Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Publication number: 20170189538Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: March 20, 2017Publication date: July 6, 2017Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 9629798Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: GrantFiled: March 26, 2009Date of Patent: April 25, 2017Assignee: MALLINCKRODT PHARMA IP TRADING D.A.C.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 8071090Abstract: Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more.Type: GrantFiled: June 13, 2008Date of Patent: December 6, 2011Assignee: Zymogenetics, Inc.Inventors: Richard I. Senderoff, Shan Jiang
-
Publication number: 20110125089Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: March 26, 2009Publication date: May 26, 2011Applicant: ZYMOGENETICS, INC.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcoa, Paul D. Bishop, Gerald W. Lasser
-
Patent number: 7473543Abstract: Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 mM CaCl2, 0.03% to 1% (w/v) of a surfactant or high-molecular-weight polyethylene glycol, and a physiologically acceptable buffer, or may be in lyophilized form.Type: GrantFiled: October 6, 2006Date of Patent: January 6, 2009Assignee: ZymoGenetics, Inc.Inventors: Shan Jiang, Richard I. Senderoff, Jeffrey D. Meyer
-
Publication number: 20080311104Abstract: Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more.Type: ApplicationFiled: June 13, 2008Publication date: December 18, 2008Inventors: Richard I. Senderoff, Shan Jiang
-
Patent number: 7393674Abstract: Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 mM CaCl2, 0.03% to 1% (w/v) of a surfactant or high-molecular-weight polyethylene glycol, and a physiologically acceptable buffer, or may be in lyophilized form.Type: GrantFiled: June 21, 2005Date of Patent: July 1, 2008Assignee: Zymogenetics, Inc.Inventors: Shan Jiang, Richard I. Senderoff, Jeffrey D. Meyer
-
Patent number: 6790439Abstract: Compositions of thrombopoietin, methods of reducing adsorption of thrombopoietin to a surface, and methods of stabilizing a composition of thrombopoietin are disclosed. The compositions comprise, in addition to thrombopoietin, a physiologically acceptable buffer, a surface adsorption inhibitor selected from the group consisting of non-ionic surfactants and polyols, and an isotonic amount of a physiologically acceptable salt.Type: GrantFiled: June 7, 1995Date of Patent: September 14, 2004Assignee: ZymoGenetics, Inc.Inventors: Richard I. Senderoff, Kathleen M. Kontor